NEOTHYLLINE
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Sep 1953
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEOTHYLLINE is an injectable small-molecule drug approved in 1953 by Teva as an NDA product. The specific indication and mechanism of action are not documented in available data, limiting characterization of its therapeutic role.
LOE Approaching
Product is in advanced lifecycle stage with LOE approaching; commercial teams are likely focused on transition planning and market defense rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate this is a legacy product with stable, minimal staffing needs. Career development on NEOTHYLLINE is limited; roles focus on lifecycle management, cost containment, and compliance rather than growth initiatives.
Brand ManagerMarket Access Manager
Worked on NEOTHYLLINE at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.